Pulmonary Embolism Clinical Trial
Official title:
Quantitative Assessment of Right Ventricular Strain Utilizing Cardiac Magnetic Resonance Imaging: Development of an Optimal Measure of Treatment Response Following Catheter-directed Interventions on Sub-massive Pulmonary Embolism.
Acute pulmonary embolism (PE) is a condition in which the vessels carrying blood to the lungs
become suddenly blocked, usually by a blood clot. There are a number of adverse consequences
that result, with one of the most significant being strain on the right side of the heart
(which must push blood through the blocked arteries to the lungs). Although this strain on
the right heart is very important, current methods for measuring it are flawed. The standard
practice is to obtain an echocardiogram (ultrasound of the heart), from which indirect
measurements of the size of the heart are used to make inferences about right heart strain.
This method can help guide management in some patients, but it in not a sensitive test and
does not provide detailed information.
Patients with PE are treated with blood thinning medications. Some patients may be referred
to the Interventional Radiology (IR) team for endovascular intervention, in which catheters
are placed into the patient's vessels under radiologic guidance and advanced to the lungs to
remove the clot entirely.
Cardiac magnetic resonance imaging (MRI) is a well-established imaging technique that
produces highly detailed images of the heart's structure and function, with no risks to
patients of ionizing radiation or intravenous contrast. Cardiac MRI is far superior to
echocardiogram in evaluation of the right side of the heart, however it has not been widely
used in the evaluation of patients with PE. We propose that by using a fast MRI protocol, we
will be able to detect right heart strain with more accuracy than echocardiogram.
Furthermore, we hypothesize that MRI images obtained before and after IR catheter-directed
therapy will demonstrate the degree to which strain is relieved with this treatment. Finally,
we believe that using MRI may help to guide management of patients with PE by detecting early
or mild heart strain before it progresses.
In order to test these hypotheses, we plan to image PE patients who have been referred to the
IR team with MRI. Patients recruited for this study will undergo two short MRI scans - one
immediately before treatment, and one after completion of IR treatment (which lasts
approximately 12-24 hours).
Pulmonary embolism occurs when embolic material (usually clot in the venous system) travels
to the heart and lodges in the pulmonary vasculature. This obstruction, if significant, can
lead to pulmonary arterial hypertension, which places increased demand on the right ventricle
(RV), which must pump against the blockage. This can manifest as right ventricular
dysfunction (RVD), which is characterized by dilatation of the RV, wall motion abnormalities
and other structural and functional changes. There is a significant body of data
demonstrating that function of the RV is an important prognostic indicator in patients with
acute PE. In these studies, RVD allowed identification of patients who, although clinically
stable on presentation, were at risk for hemodynamic instability and high
morbidity/mortality. As a result, many authors have suggested that RVD represents an
important indication for more aggressive therapy in patients with submassive PE.
Currently, echocardiography is the most commonly used method for evaluating the RV in acute
PE. However, obtaining quality imaging of the RV using echocardiography is technically
difficult, and determining a reliable indicator of RV function has proved challenging. A
number of markers of right ventricular function have been described, including size criteria,
ejection fraction, wall motion, tricuspid regurgitation, paradoxical septal motion, and
others. However, there is no general consensus on which methodology or measurements produce
the most clinically meaningful data. The American Heart Association guidelines for submassive
pulmonary embolism use the ratio of the right ventricle to left ventricle at end diastole
(RV:LV ratio), which is defined as greater than 0.9 in patients with RVD. However, there is a
large degree of heterogeneity in echocardiographic criteria for RVD used in the literature.
Additionally, the quantitative data provided by echocardiography is suspect, as they show
only modest correlation with cardiac magnetic resonance imaging (cMRI) or computed tomography
(CT) in evaluation of the RV. Even when specifically utilizing the American Society of
Echocardiography guidelines, echocardiography proves to be significantly less accurate than
cMRI for evaluation of the RV, especially in patients with a dilated ventricle.
Cardiac magnetic resonance imaging is considered the reference standard for accurate
evaluation of ventricular structure and function. It has proven its accuracy, reliability,
and prognostic value in the setting of other pathologies that result in RV dysfunction, such
as pulmonary hypertension. However, to date, this modality has not been used to provide
detailed information about the structure and function of the RV in patients with acute PE.
Recently, new therapies for acute PE have come into use that allow more precise treatment of
the embolus itself through the use of endovascular catheters. These catheter-directed
therapies (CDTs) deliver thrombolytic medication or other treatment strategies directly to
the pulmonary circulation. There is a strong body of evidence supporting the use of these
therapies, and some devices have been FDA-approved for this indication. Despite this, there
is a lack of definitive markers for the patients who would benefit most from this therapy.
Additionally, techniques currently used to attempt to quantify response to therapy (such as
RV:LV ratio) are not ideal. There remains a need for a quantitative method for evaluating the
structure and function of the RV in patients with acute PE in order to determine their risk
for hemodynamic compromise, the need for CDT, and response after therapy is completed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |